The five-membed ring of the title compound, C(11)H(13)NO, that is fused with the aromatic ring is approximately planar (r.m.s. deviation = 0.037 Å) despite the presence of the sp(3)-hybrid-ized ethyl-ene linkage. The hy-droxy group of the N-bound hy-droxy-ethyl chain serves as hydrogen-bond donor to the azomethine N atom of an adjacent mol-ecule, generating a hydrogen-bonded C(2)-symmetric dimer.
An entry from the Cambridge Structural Database, the world’s repository for small molecule crystal structures. The entry contains experimental data from a crystal diffraction study. The deposited dataset for this entry is freely available from the CCDC and typically includes 3D coordinates, cell parameters, space group, experimental conditions and quality measures.
A series of functionalized bipyrazoles, fused bipyrazoles and other related heterocyclic systems have been synthesized. The key intermediate bipyrazoles have been prepared by cyclocondensation of the appropriate chalcone with 4hydrazinobenzenesulfonamide hydrochloride. The chemistry of the reactions employed in the synthesis of the target compounds together with their chemical behaviour, are discussed and the structures of the newly synthesized compounds have been confirmed by the IR and H and C NMR spectral data. All the synthesized compounds show weak anticancer activity and weak antimicrobial and antifungal activity against some bacteria and fungi.
Abstract Ruthenium complexes are considered as the most favorable alternatives to traditional platinum-based cancer drugs owing to their acceptable toxicity level, selectivity, variant oxidation states and ability to treat platinum-resistant cancer cells. They have similar ligand exchange kinetics as platinum drugs but can be tailored according to our desire by ligands influence. In the current study, we illustrate the in-vitro anticancer profile of some ruthenium complexes (2016–2021) against human hepatocellular carcinoma (HepG2). The anticancer activity of ruthenium complexes is determined by comparing their IC 50 values with one another and positive controls. Fortunately, some ruthenium complexes including 3, 4, 6, 14, 15, 20, 42 , and 48 exhibit surpassed in-vitro anticancer profile than that of positive controls promising as potential candidates against liver cancer. We also explored the structure-activity relationship (SAR) which is a key factor in the rational designing and synthesis of new ruthenium drugs. It covers the factors affecting anticancer activity including lipophilicity, planarity, area and bulkiness, the steric influence of different ligands, and electronic effects induced by ligands, stability, aqueous solubility and bioavailability to the target sites. The data reported here will provide strong support in the plausible design and synthesis of ruthenium anticancer drugs in the upcoming days.